Literature DB >> 1898655

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

C M D'Urso1, Z G Wang, Y Cao, R Tatake, R A Zeff, S Ferrone.   

Abstract

The melanoma cell line FO-1 does not express HLA class I antigens and does not acquire them on the cell surface after incubation with IFN-gamma. Immunochemical studies showed that FO-1 cells synthesize HLA class I heavy chain, but do not synthesize beta 2-microglobulin (beta 2-mu). The latter abnormality is associated with lack of beta 2-mu mRNA which remains undetectable in FO-1 cells incubated with IFN-gamma. The defect was identified as a genetic lesion in the B2m gene, since DNA hybridization analysis detected a deletion of the first exon of the 5'-flanking region, and of a segment of the first intron of the B2m gene. HLA class I antigen expression was reconstituted on melanoma cells FO-1 after transfection with the wild-type mouse B2m gene, thereby confirming the abnormality of the endogenous B2m gene. The defect identified in FO-1 cells is distinct from that underlying the lack of HLA class I antigen expression by lymphoblastoid cells Daudi, but is remarkably similar to that causing lack of H-2 class I antigen expression by mouse lymphoblastoid cells R1 (TL-). These results suggest that genetic recombination in the 5' region of the B2m gene is a recurrent mechanism in B2m gene defects. In addition to contributing to our understanding of molecular abnormalities in HLA class I antigen expression by melanoma cells, FO-1 cells represent a useful model for analyzing the role of HLA class I antigens in the biology of melanoma cells and in their interaction with cells of the immune system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898655      PMCID: PMC295046          DOI: 10.1172/JCI114984

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6.

Authors:  A Harel-Bellan; A Quillet; C Marchiol; R DeMars; T Tursz; D Fradelizi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

2.  Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.

Authors:  P I Lobo; C E Spencer
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

Review 3.  Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.

Authors:  K Tanaka; T Yoshioka; C Bieberich; G Jay
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

4.  Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens.

Authors:  F M Brodsky; W F Bodmer; P Parham
Journal:  Eur J Immunol       Date:  1979-07       Impact factor: 5.532

5.  Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells.

Authors:  M Maio; B Gulwani; A Morgano; S Ferrone
Journal:  Int J Cancer       Date:  1989-09-15       Impact factor: 7.396

6.  High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells.

Authors:  R Versteeg; L T Peltenburg; A C Plomp; P I Schrier
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

7.  Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene.

Authors:  M E Sunday; K J Isselbacher; S Gattoni-Celli; C G Willett
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

8.  Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation.

Authors:  M C Turco; M De Felice; L Corbo; G Morrone; R Mertelsmann; S Ferrone; S Venuta
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.

Authors:  A Doyle; W J Martin; K Funa; A Gazdar; D Carney; S E Martin; I Linnoila; F Cuttitta; J Mulshine; P Bunn
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.

Authors:  B Mukherji; A Guha; N G Chakraborty; M Sivanandham; A L Nashed; J R Sporn; M T Ergin
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  82 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

Review 2.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

3.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

4.  Assembly-dependent expression of antigenic epitopes by beta 2-microglobulin(b).

Authors:  R J Tatake; R A Zeff
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

5.  Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket.

Authors:  A Kikuchi; T Sakaguchi; K Miwa; Y Takamiya; H G Rammensee; Y Kaneko; M Takiguchi
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  The heavy chain of neonatal Fc receptor for IgG is sequestered in endoplasmic reticulum by forming oligomers in the absence of beta2-microglobulin association.

Authors:  Xiaoping Zhu; Junmin Peng; Raktima Raychowdhury; Atsushi Nakajima; Wayne I Lencer; Richard S Blumberg
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

Review 7.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

8.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

9.  Rapid degradation of the heavy chain of class I major histocompatibility complex antigens in the endoplasmic reticulum of human cytomegalovirus-infected cells.

Authors:  Y Yamashita; K Shimokata; S Saga; S Mizuno; T Tsurumi; Y Nishiyama
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Authors:  D C Bicknell; A Rowan; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.